Priority Research Papers:
A new drug combination significantly reduces kidney tumor progression in kidney mouse model
Metrics: PDF 503 views | HTML 813 views | ?
Sitai Liang1, Tiffanie Cuellar1, Maciej Nowacki1, Bijaya K. Nayak1, Lily Dong1, Boajie Li3, Kumar Sharma2 and Samy L. Habib1,4
1 Department of Cell Systems & Anatomy, University of Texas Health Science Center at San Antonio, Bio-X Institutes, San Antonio, TX, USA
2 Department of Medicine, University of Texas Health Science Center at San Antonio, Bio-X Institutes, San Antonio, TX, USA
3 Shanghai Jiao Tong University, Shanghai, China
4 South Texas Veterans Health Care System, San Antonio, TX, USA
Samy L. Habib, email: firstname.lastname@example.org
Keywords: kidney tumor; rapamycin; AICAR; HIF2α; TSC2
Received: March 24, 2018 Accepted: July 27, 2018 Published: August 31, 2018
Tuberous sclerosis complex (TSC) disease is associated with tumors in many organs, particularly angiomyolipoma (AML) in the kidneys. Loss or inactivation of TSC1/2 results in high levels of HIF-α activity and VEGF expression. mTOR inhibitor (rapamycin) and the AMPK activator 5-aminoimidazole-4-carboxamide (AICA)-riboside (AICAR) are currently used separately to treat cancer patients. Here, we investigated the effect of a novel combination of rapamycin and AICAR on tumor progression. Our data show that treatment of AML human cells with drug combinations resulted in 5-7-fold increase in cell apoptosis compared to each drug alone. In addition, drug combinations resulted in 4-5-fold decrease in cell proliferation compared to each drug alone. We found that drug combinations abolished Akt and HIF activity in AML cells. The drug combinations resulted in decrease in cell invasion and cell immigration by 70% and 84%, respectively in AML cells. The combined drugs also significantly decreased the VEGF expression compare to each drug alone in AML cells. Drug combinations effectively abolished binding of HIF-2α to the putative Akt site in the nuclear extracts isolated from AML cells. Treatment TSC mice with drug combinations resulted in 75% decrease in tumor number and 88% decrease in tumor volume compared to control TSC mice. This is first evidence that drug combinations are effective in reducing size and number of kidney tumors without any toxic effect on kidney. These data will provide evidence for initiating a new clinical trial for treatment of TSC patients.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.